These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20707611)

  • 1. Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1265-76. PubMed ID: 20707611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin and metformin--novel combination therapy.
    Seyoum B
    Expert Opin Pharmacother; 2011 Mar; 12(4):641-6. PubMed ID: 21291346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study.
    Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM
    Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.
    Chwieduk CM
    Drugs; 2011 Feb; 71(3):349-61. PubMed ID: 21319871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
    Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
    Williams-Herman D; Xu L; Teng R; Golm GT; Johnson J; Davies MJ; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Jan; 14(1):67-76. PubMed ID: 22050786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
    Gallwitz B
    Drugs Today (Barc); 2007 Oct; 43(10):681-9. PubMed ID: 17987221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ
    Clin Pharmacokinet; 2010 Sep; 49(9):573-88. PubMed ID: 20690781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janumet: a combination product suitable for use in patients with Type 2 diabetes.
    Reynolds JK; Neumiller JJ; Campbell RK
    Expert Opin Investig Drugs; 2008 Oct; 17(10):1559-65. PubMed ID: 18808315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
    Scheen AJ
    Diabetes Obes Metab; 2010 Aug; 12(8):648-58. PubMed ID: 20590741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
    Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
    Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New combination treatments in the management of diabetes: focus on sitagliptin-metformin.
    Green J; Feinglos M
    Vasc Health Risk Manag; 2008; 4(4):743-51. PubMed ID: 19065992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
    Herman GA; Bergman A; Yi B; Kipnes M;
    Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2013 Mar; 9(3):363-77. PubMed ID: 23373842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical review of sitagliptin: a DPP-4 inhibitor.
    Garg K; Tripathi CD; Kumar S
    J Assoc Physicians India; 2013 Sep; 61(9):645-9. PubMed ID: 24772702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):745-58. PubMed ID: 22587686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
    Choy M; Lam S
    Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.